The Pharma Closeout's ASTRO 2026 Debrief covers the readouts from the American Society for Radiation Oncology meeting that matter for drug,diagnostic and payer strategy. Fourteen-year RTOG 0815 data re-open how much hormone therapy men need with prostate radiation, as Veracyte's Decipher andArtera compete to decide who can skip it. The NRG-GI003 plenary showed no survival improvement for protons over photons in liver cancer, Novocure's TRIDENT timing trial missed, and new data arrived on PSMA imaging, radioligands, SBRT versus surgery and lung immunotherapy after SABR. Plus what to watch: theLantheus shareholder vote on the Curium takeover.0:00 Introduction1:17 Story of the Congress: who still needs hormone therapy with radiation9:29 Prostate: PSMA imaging, PSMA-guided radiation and SBRT vs surgery13:20 Radioligand therapy at a radiation meeting17:08 Glioblastoma: TRIDENT and Tumor Treating Fields timing18:51 Lung: immunotherapy after SABR20:46 Liver and rectal: protons vs photons, and PD-1 in rectal cancer23:45 Breast: endocrine adherence and skipping radiation24:51 What to watch: the Lantheus voteAlex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →